These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23369416)

  • 1. HIV and coronary heart disease: time for a better understanding.
    Boccara F; Lang S; Meuleman C; Ederhy S; Mary-Krause M; Costagliola D; Capeau J; Cohen A
    J Am Coll Cardiol; 2013 Feb; 61(5):511-23. PubMed ID: 23369416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries.
    Lang S; Boccara F; Mary-Krause M; Cohen A
    Arch Cardiovasc Dis; 2015 Mar; 108(3):206-15. PubMed ID: 25725995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus and atherosclerosis.
    Farrugia PM; Lucariello R; Coppola JT
    Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.
    Bucher HC; Rickenbach M; Young J; Glass TR; Vallet Y; Bernasconi E; Cavassini M; Fux C; Schiffer V; Vernazza P; Weber R; Battegay M;
    Antivir Ther; 2010; 15(1):31-40. PubMed ID: 20167989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
    Boccara F
    AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risks of antiretroviral therapies.
    Mondy K; Tebas P
    Annu Rev Med; 2007; 58():141-55. PubMed ID: 17217329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial and platelet function alterations in HIV-infected patients.
    Gresele P; Falcinelli E; Sebastiano M; Baldelli F
    Thromb Res; 2012 Mar; 129(3):301-8. PubMed ID: 22192157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atherosclerosis in HIV-positive patients].
    Neumann T; Miller M; Esser S; Gerken G; Erbel R
    Z Kardiol; 2002 Nov; 91(11):879-88. PubMed ID: 12442190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary artery disease in patients with HIV infection.
    Patel AA; Budoff MJ
    Am J Cardiovasc Drugs; 2015 Apr; 15(2):81-7. PubMed ID: 25672641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.